We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Crowdfunding Opportunities


Driftrock are a digitasl media media marketing company who specialise in creating simple easy to use advertising tools.
investment: £800,278 target: £600,002 pre-money valuation: £5,702,540
status: Stretch
More Information
133%
SENSEi Technology EIS
SENSEi has developed a technology platform that provides complete transparency not only on the location of people, assets and things but also their surrounding environment. Lead investor Kevin Lewis has run Blackhawk Capital LLP for the past 10 years.
investment: £266,747 target: £700,000 pre-money valuation: £1,800,000
status: Funded
More Information
38%
KiteEdge's Apex Technology EIS
Kite edge has created a cognitive search service which has been built to specifically meet the needs of asset managers. Individuals can search and set up feeds that draw insight from their specific work (email, news, investment research, internal documents)
investment: £433,000 target: £600,000 pre-money valuation: £2,694,893
status: Funded
More Information
72%
Arca is helping to build the market for property market risk transfer by dealing in derivatives for domestic and commercial properties. Nick Ruddell has held senior roles for the last 30 years with banks and big interdealer brokers.
investment: £676,500 target: £1,500,000 pre-money valuation: £6,000,000
status: Funded
More Information
45%
A wind turbine's generator currently uses rare-earth magnets which cost £40 per kg, Greenspur have developed innovative generators which use ferrite magnets, an abundantly available material, that cost as little as £1 per kg. The company have made further advancements by removing the gearbox, which has resulted in lower maintenance costs and improved efficiency.
investment: £368,640 target: £500,000 pre-money valuation: £2,340,909
status: Active
More Information
74%
Redag Crop Protection Limited Catering, Food and Drink EIS
Redag Crop is an agrochemical discovery business focused on products that play a vital role in controlling the pests and diseases that threaten our global food supply. The growing population, expected to grow by 8 billion by 2020 and then 9 billion by 2050, will need more crops than the existing land can produce. Each hectare will need to produce 2.5 times as many crops as they do now. 
investment: £1,250,000 target: £1,250,000 pre-money valuation: £12,638,889
status: Extended
More Information
100%
Bivictrix Therapeutics Limited Medical EIS SEIS
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
investment: £451,506 target: £430,000 pre-money valuation: £4,347,778
status: Extended
More Information
105%
CELLMED Medical EIS
Cellmed is an immuno-oncology company that are developing treatments for ovarian cancer.  Their lead product PROCURE a dendritic cell vaccine and they are now looking to expand the treatment to target solid tumors.    
investment: £520,294 target: £500,000 pre-money valuation: £2,400,232
status: Stretch
More Information
104%
Kings Mill Development Phase 2 - Interim Equity Housing and Property
An opportunity to invest in the development of a collection of stylish new homes consisting, in total, of 43x, 2 and 3 bed houses and 103x, 1 and 2 bed apartments.   This significant development by Prosperity will bring much needed housing stock to meet the demand from first time buyers as well as from the rental market. The development will be carried out in four phases and a proportion of each phase has been purchased by Prosperity to be sold onto investment buyers.   We are raising equity for the purchase of the site (Subject To Planning) in tranches linked to each Phase. Phase 2 will provide 17x, 2 bed houses and 3x, 3 bed houses, all to be completed within the first 18 months of the build program. All the 2 bed houses are pre-sold to Prosperity generating nearly £2m of sales revenue, and the 3 bed houses will be sold off-plan to local buyers.   The developer has secured the site and is contributing £300k of the total equity, with the remainder coming from CrowdLords Investors. In return for an investment in this Phase, holders of Redeemable Class C shares will receive 45.6% of their share of the projected profit which equates to around 39% of projected Phase 2 net profits, after tax. This will be paid as a capital gain when the shares are redeemed at a price of £1.30 per share, on or before the 28th February 2019.  
investment: £149,299 target: £333,300
status: Active
More Information
45%
YProTech provide a specialist service for the pharmaceutical, biotechnology (life sciences) and applied chemical sectors. They provide a fast and reliable delivery of laboratory scale chemistry development services.
investment: £234,438 target: £134,000 pre-money valuation: £1,354,889
status: Extended
More Information
175%
Using a person's face, the next generation of push notification allows a company to send and receive video and audio messages through the service to improve engagement and build trust with their business partners. 2Mee has attained a contract with a prominent gaming company, as well as six other clients taking a keen interest in the product and potentially licensing the IP.
investment: £411,620 target: £300,000 pre-money valuation: £4,197,751
status: Stretch
More Information
137%
Pertinax Pharma Medical EIS
Infections can be reduced and patient quality of life can be improved by using antimicrobial wound care materials developed by Pertinax. In vitro studies have already been performed using the company's development across multiple applications.
investment: £616,916 target: £699,997 pre-money valuation: £1,799,992
status: Active
More Information
88%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph